Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases

doi:10.3748/wjg.v23.i26.4796

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8168)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

548

WORD

345

HTML

4156

Figures (1-3)

308

Tables (1-6)

293

Sum=5650

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1009

Download

1509

Sum=2518

Jul 14, 2017 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jul 14, 2017; 23(26): 4796-4805
Published online Jul 14, 2017. doi: 10.3748/wjg.v23.i26.4796

Table 1 Characteristics of the studied subjects n (%)

	Ulcerative colitis	Crohn’s disease	Control group
	n = 47	n = 38	n = 50
Men	22 (46.81)	20 (52.63)	35 (70)
Age, yr	37 (26-47)^b	29.5 (22-34)^a	36 (29-46)
BMI, kg/m²	22.1 (20.5-25)	20.43 (18.38-22.9)	23.9 (22.2-25.3)
Smoking	9 (19.15)	15 (39.47)	17 (34)
Disease duration, yr	5 (2.5-9)	3.5 (2-6)	NA
Surgery	0 (0)^b	11 (28.9)	NA
Complications	3 (6.4)^b	11 (28.9)	NA
Location
Rectum	7 (14.9)	NA	NA
Left-sided	25 (53.2)	NA	NA
Extensive colitis	15 (31.9)	NA	NA
Ileal	NA	12 (31.6)	NA
Colonic	NA	3 (7.9)	NA
Ileocolonic	NA	23 (60.5)	NA
Pregnancies, n	17	12	13
Miscarriages, n	0	1	1

^aP < 0.05 vs the control group,

^bP < 0.05 vs the Crohn’s disease group. BMI: Body mass index.

Table 2 Comparison of active and inactive ulcerative colitis groups and controls

	Ulcerative colitis inactive	Ulcerative colitis active	Control group
	n = 21	n = 26	n = 50
Disease activity index (points)	2.33 ± 1.68^b	7.96 ± 1.91	NA
White blood cells, × 10³/μL	6.89 (4.91-7.74)	8.22 (5.54-9.65)	6.75 (6.1-7.9)
Platelet coun, × 10³/μL	286.02 (216-303)^b	326 (252-379)^a	229.5 (199-268)
Haematocrit (%)	43.4 (39.95-44.55)^b	39.85 (36.8-42.2)	41.1 (39.5-43)
Haemoglobin, g/dL	13.5 ± 1.67	12.7 ± 1.5^a	14.3 ± 1.1
Fibrinogen, g/L	2.52 (2.19-3.92)^b	4.97 (3.83-6.99)^a	3.05 (2.48-4.16)
CRP, mg/L	1.24 (0.79-1.89)^b	10.7 (7.22-20.8)^a	1.68 (.98-2.24)

^aP < 0.05 vs the control group,

^bP < 0.05 vs active ulcerative colitis group. CRP: C-reactive protein.

Table 3 Comparison of active and inactive Crohn’s disease groups and controls

	Crohn’s disease inactive	Crohn’s disease active	Control group
	n = 16	n = 22	n = 50
CDAI (points)	83.38 ± 33.30^b	236.05 ± 63.46	NA
White blood cells, × 10³/μL	6.74 (5.47-7.08)	6.71 (4.91-9.02)	6.75 (6.1-7.9)
Platelet count, × 10³/μL	291.5 (209-336)^b	324.5 (289-386)^a	229.5 (199-268)
Haematocrit, %	42.7 (39.75-45.1)^b	37.9 (35.8-39.8)^a	41.1 (39.5-43)
Haemoglobin, g/dL	13.99 ± 1.36^b	12.15 ± 1.4^a	14.3 ± 1.1
Fibrinogen, g/L	3.81 (2.63-4.7)^b	6.52 (4.76-8.26)^a	3.05 (2.48-4.16)
CRP, mg/L	2.95 (1.19-5.72)^b	33.8 (16.4-72.3)^a	1.68 (0.98-2.24)

^aP < 0.05 vs the control group,

^bP < 0.05 vs active Crohn’s disease group. CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

Table 4 Characteristics of markers in active and inactive ulcerative colitis groups and controls

	Ulcerative colitis inactive	Ulcerative colitis active	Control group
	n = 21	n = 26	n = 50
VWF:RCo, IU/dL	120.61 ± 36.33	134.2 ± 46.7	114.03 ± 24.67
VWF:Ag, IU/dL	139.6 (110.3-166.5)^a	144.95 (120.8-180.5)^a	106.65 (90.7-122.5)
VWF:CB, IU/dL	84.93 ± 13.88^a	78.87 ± 14.99^a	97.99 ± 10.3
ADAMTS13: Ag (IU/dL)	86.15 ± 10.17^a,^b	66.39 ± 11.45^a	103.86 ± 10.84
ADAMTS13act (IU/dL)	81.2 (79.4-92.9)^b	65.05 (55.7-75.1)^a	111.0 (97.8-122.8)
VWF:RCo/VWF:Ag	0.96 (0.92-0.97)	0.97 (0.87-1.01)	0.97 (0.91-1.15)
VWF:CB/VWF:Ag	0.68 (0.50-0.79)^a	0.5 (0.45-0.70)^a	0.91 (0.80-1.05)
VWF:Ag/ADAMTS13act	1.54 (1.34-2.07)^a	2.22 (1.65-2.84)^a	0.98 (0.79-1.20)
ADAMTS13act/ADAMTS13:Ag	1.01 (0.97-1.02)	1.0 (0.97-1.03)	1.02 (0.94-1.18)

^aP < 0.05 vs the control group,

^bP < 0.05 vs active ulcerative colitis group.

Table 5 Characteristics of markers in active and inactive Crohn’s disease groups and controls

	Crohn’s disease inactive	Crohn’s disease active	Control group
	n = 16	n = 22	n = 50
VWF:RCo, IU/dL	143.47 ± 46.12	157.04 ± 61.03^a	114.03 ± 24.67
VWF:Ag, IU/dL	135.4 (116.85-175.65)^a	182.98 (130.4-219.8)^a	106.65 (90.7-122.5)
VWF:CB, IU/dL	98.85 (86.15-102.25)	89.3 (80.6-99.7)	98.05 (91.9-101.8)
ADAMTS13:Ag, IU/dL	104.44 ± 9.96	99.29 ± 15.33	103.86 ± 10.84
ADAMTS13act, IU/dL	104.82 ± 8.61	94.48 ± 15.74^a	111.05 ± 17.69
VWFRCo/VWF:Ag	0.96 (0.95-1.00)	0.96 (0.79-1.01)	0.97 (0.91-1.15)
VWF:CB/VWF:Ag	0.65 (0.45-0.87)^a	0.54 (0.45-0.65)^a	0.91 (0.80-1.05)
VWF:Ag/ADAMTS13act	1.26 (1.12-1.62)^a	1.88 (1.48-2.56)^a	0.98 (0.79-1.20)
ADAMTS13act/ADAMTS13:Ag	0.99 (0.94-1.05)	0.96 (0.92-1.03)	1.02 (0.94-1.18)

^aP < 0.05 vs the control group.

Table 6 Results of multiple linear regression in ulcerative colitis patients

	ADAMTS13:Ag	ADAMTS13act
Platelets	β = -0.03 (95%CI: -0.07; -0.01)	-
	P = 0.044
C-reactive protein	β = -0.19 (95%CI: -0.33; -0.05)	β = -0.25 (95%CI: -0.38; -0.12)
	P = 0.103	P < 0.001
Disease activity	β = -2.27 (95%CI: -3.18; -1.35)	β = -0.2.27 (95%CI: -3.48; -1.86)
	P < 0.001	P < 0.001
adj.R²	65.3%	69.5%

Results show the estimated value of parameter, P-value for the t-test and adjusted determinant coefficient. Additional, 95%CI of parameter’s estimate when P < 0.05. adj.R²: Adjusted determinant coefficient.

Citation: Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. World J Gastroenterol 2017; 23(26): 4796-4805
URL: https://www.wjgnet.com/1007-9327/full/v23/i26/4796.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i26.4796